Replimune Group, Inc. — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Replimune amended its Certificate of Incorporation effective September 15, 2026, increasing total authorized capital stock from an unstated prior level to 310 million shares: 300 million common shares and 10 million preferred shares, each at $0.001 par value. The amendment was adopted by the Board of Directors and stockholders per Delaware law Section 242. No specific prior authorization level, issuance plan, or financing context is disclosed in this filing.
Why this rating
Routine capital authorization increase; no imminent issuance, dilution, financing, or M&A disclosed. Standard corporate housekeeping; modest relative to $234.5M market cap if used, but intent unclear.
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.